OPDIVO® Receives Two New Health Canada Approvals for: Use with Chemotherapy for the Treatment for Patients with HER2 Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Cancers; Use as Monotherapy for the Adjuvant Treatment for Patients with Completely Resected Esophageal or Gastroesophageal Junction Cancers Pharmaceutical Investing
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors Biotech Investing
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Pharmaceutical Investing
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Lupus Nephritis Pharmaceutical Investing
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol Cannabis Investing News
AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 Pharmaceutical Investing
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937 Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
U.S. Food and Drug Administration Approves VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia Pharmaceutical Investing
NATERA Plant-Based, Meat Alternative Entrees Now Available in Denny's Restaurants Across Canada Cannabis Investing News
